An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...

Death rates and disability in newborn PAH have declined globally since 1990, but inequalities remain, according to a 30-year ...

The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinical worsening among adults with pulmonary arterial hypertension (PAH) who were ...

Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...

Sotatercept reduced patient’s risk of deterioration by 76% due to pulmonary hypertension, or high blood pressure in the heart-to-lung system, researchers reported recently in the New England Journal ...

Patients were better able to keep exercising and avoid unexpected hospitalizations MONDAY, Oct. 6, 2025 (HealthDay News) — A recently approved injectable drug can significantly stall deteriorating ...

MONDAY, Oct. 6, 2025 (HealthDay News) — A recently approved injectable drug can significantly stall deteriorating health among people newly diagnosed with the most severe form of high blood pressure, ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that its investigational therapy ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

The final, formatted version of the article will be published soon. Rationale: Influenza-associated pulmonary aspergillosis (IAPA) is a great clinical challenge, which has high morbidity and mortality ...

For recently diagnosed pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to standard care lowered the risk of clinical worsening, the randomized HYPERION trial showed. Among 320 ...